Lytgobi Futibatinib Tablets, 20mg Daily Dose

Description

What is Lytgobi (futibatinib)?

Lytgobi (futibatinib) is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

Lytgobi is taken as a tablet by mouth once a day, with or without food.

Where was Lytgobi (futibatinib) approved?

On September 30, 2022, the Food and Drug Administration in the USA has granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.